Cure My Disease

Don't miss your cure!

 Log in / Sign up

Bladder cancer breakthrough? new combo aims to save the bladder

NCT ID NCT07717242

Recruiting now Disease control Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Source: ClinicalTrials.gov ↗

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding one of four different drugs to a standard immunotherapy combination can help people with HER2-positive muscle-invasive bladder cancer avoid bladder removal. Participants receive disitamab vedotin and toripalimab plus a sensitizing agent, then are assessed for complete response. Those who respond may continue on a bladder-preserving path instead of surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a combination of disitamab vedotin (a targeted antibody-drug conjugate), toripalimab (an immunotherapy), and one of four sensitizing agents (sitagliptin, tazemetostat, tafolecimab, or ursodeoxycholic acid)
What this could lead to
If successful, this could offer a way to treat muscle-invasive bladder cancer without removing the bladder, preserving quality of life.
What could go wrong
This is an early-phase trial with a small number of participants, so results may not apply broadly. The combination therapies may cause side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bladder transitional cell carcinoma infiltrating bladder urothelial carcinoma transitional cell carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CANCER BLADDER UROTHELIAL CARCINOMA

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Sun Yat-sen Memorial Hospital

    RECRUITING

    Guangzhou, Guangdong, 510000, China

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.